DiviTum® TKa

by info@quimark.com | 8 July 2025 | Products | 0 Comments

DiviTum® TKa Quantitative Test for the Evaluation of Metastatic Tumor Proliferation Utility of Divitum TKa The DiviTum® TKa test measures the activity of thymidine kinase 1 (TK1) in the blood, an enzyme released by proliferating tumor cells....

Canhelp® Origin

by info@quimark.com | 21 March 2025 | Products | 0 Comments

Canhelp® - Origin Diagnostic Test for the Identification of the Origin of a Tumor How Canhelp-Origin Is Useful Canhelp-Origin is a molecular test used on FFPE tumor tissue samples to identify the primary site of a metastatic tumor, particularly...

Canhelp®-UCa

by admin | 20 January 2025 | Products | 0 Comments

Canhelp®-UCa CE-IVD Diagnostic Test for Urothelial Cancer Usefulness of Canhelp-UCa Current guidelines for urothelial carcinoma support a diagnostic approach based on cystoscopy combined with sample urine cytology. The...

BiomeOne®

by info@quimark.com | 25 September 2024 | Products | 0 Comments

BiomeOne® Microbiota Analysis for Immunotherapy The first microbiota-based test to help predict response to cancer immunotherapy. What is BiomeOne? BiomeOne is the first CE-IVD fecal sample test that can help predict...

MyRisk® Plus

by info@quimark.com | 4 June 2024 | Products | 0 Comments

MyRisk® Plus Multigene Germline Test for Hereditary Cancer How Does MyRisk Plus Help? MyRisk is a multigene germline blood test that can help determine a patient's hereditary cancer risk by focusing on eleven of the most common hereditary cancers....

MyChoice®CDx PLUS

by admin | 3 May 2024 | Products | 0 Comments

MyChoice®CDx PLUS HRD Test on Tumor Tissue Detection of Homologous Recombination Deficiency (HRD) in Ovarian Cancer. MyChoice CDx Plus is a genomic test that guides medical decisions in treating ovarian cancer with PARP inhibitors. The test is...

Prolaris®

by admin | 3 May 2024 | Products | 0 Comments

Prolaris® Genomic Prostate Cancer Test: How Prolaris Can Help Prolaris is a prognostic genomic test for prostate cancer, developed to help healthcare providers predict tumor aggressiveness. Prolaris is indicated for patients who have received...

EndoPredict®

by admin | 14 March 2024 | Products | 0 Comments

EndoPredict® Second-Generation Genomic Breast Cancer Test. How EndoPredict Benefits. EndoPredict is a prognostic-predictive test for early-stage, hormone receptor-positive (ER+/HER2-) breast cancer. EndoPredict has been shown to: predict...

For information



Telephone

+39 0240090222



E-mail

oncology@did.it

The content of this website is informative about the Quimark company and its products and services,
It is not intended as professional medical or health advice.

Starting from October 7, 2025, Quimark Srl merged by incorporation with DID SpA, a company integrated into the group Eurobio Scientific.

This operation strengthens our strategic positioning in the diagnostic-oncology sector, thanks to the synergies with the activities already carried out by DID and with the expertise of the Eurobio group.

For information

Telephone

E-mail

Send a message